Pfizer terminates an early-stage STING agonist trial

Kyle LaHucik

Senior Reporter

Pfizer’s pipeline prioritization has now turned to a STING agonist, with an early-stage study termination of the asset, a spokesperson confirmed to Endpoints News. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer terminates an early-stage STING agonist trial

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

MoonLake's CEO on its looming mid-year pivotal readout in skin disease

Merck diversity leader to retire this summer; Geron seeks commercial chops for next CEO

RFK Jr. convened roundtable around ways to reduce stem cell regulation

Sutro slashes workforce in half, changes CEO and closes factory

Lilly-partnered Fauna Bio plans $40M Series A to get into heart failure

Obesity drug development—still room to grow

Pfiz­er ter­mi­nates an ear­ly-stage STING ag­o­nist tri­al

Senior Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Pfizer terminates an early-stage STING agonist trial